


### AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, and listings, of claims in the Application:

#### Listing of Claims

1. (Currently amended) A compound of the Formula (I-1):



I-1

wherein:

X is alkylene ~~optionally interrupted by one or more O groups~~;

Z is -C(O)-;

R<sub>1-1</sub> is selected from the group consisting of:

hydrogen,

alkyl,

phenyl,

-N(CH<sub>3</sub>)(OCH<sub>3</sub>), and

alkyl or phenyl, substituted by one or more substituents selected from the group

consisting of:

halogen,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy, and

alkyl; and

R<sub>2</sub> is selected from the group consisting of:

hydrogen,  
alkyl,  
hydroxyalkyl, and  
alkyloxyalkyl;

R<sub>A</sub> and R<sub>B</sub> are taken together to form either a fused aryl ring that is unsubstituted or substituted by one or more R groups, or a fused 5 to 7 membered saturated ring that is unsubstituted or substituted by one or more R<sub>a</sub> groups;

R is selected from the group consisting of:


fluoro,  
alkyl,  
haloalkyl,  
alkoxy, and  
-N(R<sub>9</sub>)<sub>2</sub>; and

R<sub>a</sub> is selected from the group consisting of:

halogen,  
hydroxy,  
alkyl,  
alkenyl,  
haloalkyl,  
alkoxy,  
alkylthio, and  
-N(R<sub>9</sub>)<sub>2</sub>;

or a pharmaceutically acceptable salt thereof.

2. (Currently amended) A compound of the Formula (I-2):



I-2

wherein:

X is alkylene ~~optionally interrupted by one or more O groups~~;

n is an integer from 0 to 4;

Z is -C(O)-;

R<sub>1-1</sub> is selected from the group consisting of:

hydrogen,

alkyl,

phenyl,

-N(CH<sub>3</sub>)(OCH<sub>3</sub>), and

alkyl or phenyl, substituted by one or more substituents selected from the group

consisting of:

halogen,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy, and

alkyl;

R is selected from the group consisting of:

fluoro,

alkyl,

haloalkyl,

alkoxy, and

-N(R<sub>9</sub>)<sub>2</sub>;


R<sub>2</sub> is selected from the group consisting of:

hydrogen,  
alkyl,  
hydroxyalkyl, and  
alkyloxyalkyl; and

R<sub>9</sub> is selected from the group consisting of hydrogen and alkyl;  
or a pharmaceutically acceptable salt thereof.

3.-4. (Canceled)

5. (Currently amended) A compound of the Formula (Ia):



wherein:

X is alkylene ~~optionally interrupted by one or more O groups;~~

n is an integer from 0 to 4;

R<sub>1-1</sub> is selected from the group consisting of:

hydrogen,  
alkyl,  
phenyl,  
-N(CH<sub>3</sub>)(OCH<sub>3</sub>), and

alkyl or phenyl, substituted by one or more substituents selected from the group  
consisting of:

halogen,  
alkoxy,  
dialkylamino,

alkylthio,  
haloalkyl,  
haloalkoxy, and  
alkyl;

R is selected from the group consisting of:

fluoro,  
alkyl,  
haloalkyl,  
alkoxy, and  
-N(R<sub>9</sub>)<sub>2</sub>;


R<sub>2</sub> is selected from the group consisting of:

hydrogen,  
alkyl,  
hydroxyalkyl, and  
alkyloxyalkyl; and

R<sub>9</sub> is selected from the group consisting of hydrogen and alkyl;  
or a pharmaceutically acceptable salt thereof.

6.-7. (Canceled)

8. (Currently amended) A compound of the Formula (Ie):



wherein:

X is alkylene ~~optionally interrupted by one or more O groups;~~

n is an integer from 0 to 4;

R is selected from the group consisting of:

fluoro,  
alkyl,  
alkoxy,  
haloalkyl, and  
-N(R<sub>9</sub>)<sub>2</sub>;

R<sub>2</sub> is selected from the group consisting of:

hydrogen,  
alkyl,  
hydroxyalkyl, and  
alkyloxyalkyl; and

R<sub>9</sub> is selected from the group consisting of hydrogen and alkyl;  
or a pharmaceutically acceptable salt thereof.

9.-10. (Canceled)

11. (Previously presented) The compound or salt of claim 2 wherein n is 0.

12.-17. (Canceled)

18. (Previously presented) The compound or salt of claim 1 wherein R<sub>1-1</sub> is selected from the group consisting of phenyl, alkyl, and -N(CH<sub>3</sub>)OCH<sub>3</sub>.

19. (Canceled)

20. (Currently amended) The compound or salt of claim 1 wherein X is ~~[[a]]~~ C<sub>1-6</sub> alkylene ~~or~~ ~~(CH<sub>2</sub>)<sub>2-4</sub>-O-(CH<sub>2</sub>)<sub>1-3</sub>-~~.

21. (Currently amended) The compound or salt of claim 20 wherein X is selected from the group consisting of  $-(\text{CH}_2)_{1-6}-$ ,  $-\text{CH}_2-\text{C}(\text{CH}_3)_2-$ ,  ~~$-(\text{CH}_2)_2-\text{O}-\text{CH}_2-$~~ ,  ~~$-(\text{CH}_2)_3-\text{O}-\text{CH}_2-$~~ , and  $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{CH}_2-$ .
22. (Previously presented) The compound or salt of claim 1 wherein  $\text{R}_{1-1}$  is selected from the group consisting of alkyl and phenyl.
23. (Previously presented) The compound or salt of claim 1 wherein  $\text{R}_{1-1}$  is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.
- 24.-25. (Canceled)
26. (Previously presented) The compound or salt of claim 1 wherein  $\text{R}_2$  is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.
- 27.-28. (Canceled)
29. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 in combination with a pharmaceutically acceptable carrier.
30. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.
31. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

32. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

33.-35. (Canceled)

36. (Currently amended) The compound or salt of claim 2 wherein X is  $[[a]]$  C<sub>1-6</sub> alkylene or ~~(CH<sub>2</sub>)<sub>2-4</sub>-O-(CH<sub>2</sub>)<sub>1-3</sub>-~~.

37. (Currently amended) The compound or salt of claim 36 wherein X is selected from the group consisting of -(CH<sub>2</sub>)<sub>1-6</sub>-, -CH<sub>2</sub>-C(CH<sub>3</sub>)<sub>2</sub>-, ~~(CH<sub>2</sub>)<sub>2</sub>-O-CH<sub>2</sub>-~~, ~~(CH<sub>2</sub>)<sub>3</sub>-O-CH<sub>2</sub>-~~, and -CH<sub>2</sub>-C(CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-.

38. (Previously presented) The compound or salt of claim 2 wherein R<sub>1-1</sub> is selected from the group consisting of alkyl and phenyl.

39. (Previously presented) The compound or salt of claim 2 wherein R<sub>1-1</sub> is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.

40. (Canceled)

41. (Previously presented) The compound or salt of claim 2 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.

42. (Previously presented) A pharmaceutical composition comprising a therapeutically



effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.

43. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.

44.-53. (Canceled)

54. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 8 in combination with a pharmaceutically acceptable carrier.

55. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 8 to the animal.